Skip to content

Translational Psychiatry

ISSN 2158-3188

151 papers in the library · 4,545 citations · publishing 2012-2026

Papers

Sort Most recent Most cited

IGF-1 release in the medial prefrontal cortex mediates the rapid and sustained antidepressant-like actions of ketamine

Translational Psychiatry May 17, 2022 Satoshi Deyama, M. Kondo, Shoichi Shimada et al.

Ketamine, an N-methyl-D-aspartate receptor antagonist, exerts rapid and sustained antidepressant actions. Preclinical studies demonstrated that the release of brain-derived neurotrophic factor (BDNF) and vascular endothelial growth factor in the medial prefrontal cortex (mPFC) is essential for the antidepressant-like effects of ketamine. However, the role of other neurotrophic factors in the...

MDMA treatment paired with a trauma-cue promotes adaptive stress responses in a translational model of PTSD in rats

Translational Psychiatry May 3, 2022 Shira Arluk, Michael A. Matar, Lior Carmi et al. 19 citations

AbstractMDMA (3,4-methylenedioxymethamphetamine), a synthetic ring-substituted amphetamine, combined with psychotherapy has demonstrated efficacy for the treatment of chronic posttraumatic stress disorder (PTSD) patients. This controlled prospective study aimed to assess the bio-behavioral underpinnings of MDMA in a translational model of PTSD. Rats exposed to predator-scent stress (PSS) were...

Comparative metabolomic analysis in plasma and cerebrospinal fluid of humans and in plasma and brain of mice following antidepressant-dose ketamine administration

Translational Psychiatry May 2, 2022 Ruin Moaddel, Panos Zanos, Cristan A Farmer et al. 32 citations

Abstract Subanesthetic-dose racemic ( R,S )-ketamine (ketamine) produces rapid, robust, and sustained antidepressant effects in major depressive disorder (MDD) and bipolar disorder (BD) and has also been shown to effectively treat neuropathic pain, complex regional pain syndrome, and post-traumatic stress disorder (PTSD). However, to date, its mechanism of action remains unclear. Preclinical...

Psilocin acutely alters sleep-wake architecture and cortical brain activity in laboratory mice

Translational Psychiatry February 23, 2022 Trevor Sharp, Christopher W. Thomas, Cristina Blanco-Duque et al. 40 citations

Abstract Serotonergic psychedelic drugs, such as psilocin (4-hydroxy-N,N-dimethyltryptamine), profoundly alter the quality of consciousness through mechanisms which are incompletely understood. Growing evidence suggests that a single psychedelic experience can positively impact long-term psychological well-being, with relevance for the treatment of psychiatric disorders, including depression. A...

DOI: 10.1038/s41398-022-01846-9 (opens in new tab) Full text (opens in new tab) Sleep architecture Sleep system call Schizophrenia object-oriented programming Electroencephalography +3

Whole blood transcriptional signatures associated with rapid antidepressant response to ketamine in patients with treatment resistant depression

Translational Psychiatry January 10, 2022 F. Cathomas, L. Bevilacqua, Aarthi Ramakrishnan et al. 44 citations

Ketamine has rapid and sustained antidepressant effects in patients with treatment-resistant depression (TRD). However, the underlying mechanisms of action are not well understood. There is increasing evidence that TRD is associated with a pro-inflammatory state and that ketamine may inhibit inflammatory processes. We thus investigated whole blood transcriptional profiles related to TRD and...

Lithium augmentation of ketamine increases insulin signaling and antidepressant-like active stress coping in a rodent model of treatment-resistant depression

Translational Psychiatry November 25, 2021 Blair J. Price, Brooke Morath, Mayo Clinic et al.

Lithium, a mood stabilizer and common adjunctive treatment for refractory depression, shares overlapping mechanisms of action with ketamine and enhances the duration of ketamine’s antidepressant actions in rodent models at sub-therapeutic doses. Yet, in a recent clinical trial, lithium co-treatment with ketamine failed to improve antidepressant outcomes in subjects previously shown to respond...

Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder.

Translational Psychiatry November 8, 2021 Manoj K. Doss, Michal Považan, Monica D Rosenberg et al. 343 citations

Psilocybin has shown promise for the treatment of mood disorders, which are often accompanied by cognitive dysfunction including cognitive rigidity. Recent studies have proposed neuropsychoplastogenic effects as mechanisms underlying the enduring therapeutic effects of psilocybin. In an open-label study of 24 patients with major depressive disorder, we tested the enduring effects of psilocybin...

Body-mind relaxation meditation modulates the thalamocortical functional connectivity in major depressive disorder: a preliminary resting-state fMRI study.

Translational Psychiatry October 23, 2021 Fangfang Chen, Xueyu Lv, Jiliang Fang et al.

Mindfulness-based interventions such as meditation have increasingly been utilized for the treatment of psychological disorders and have been shown to be effective in the treatment of depression and relapse prevention. However, it remains largely unclear the neural mechanism of the therapeutic effects of meditation among depressed individuals. In this study, we investigated how body-mind...

Psilocin, LSD, mescaline, and DOB all induce broadband desynchronization of EEG and disconnection in rats with robust translational validity

Translational Psychiatry October 2, 2021 Čestmír Vejmola, Filip Tylš, Václava Piorecká et al. 41 citations

Abstract Serotonergic psychedelics are recently gaining a lot of attention as a potential treatment of several neuropsychiatric disorders. Broadband desynchronization of EEG activity and disconnection in humans have been repeatedly shown; however, translational data from animals are completely lacking. Therefore, the main aim of our study was to assess the effects of tryptamine and...

miR-98-5p plays a critical role in depression and antidepressant effect of ketamine

Translational Psychiatry September 3, 2021 Chao Huang, Yuanyuan Wang, Zifeng Wu et al. 29 citations

Ketamine has been demonstrated to be a rapid-onset and long-lasting antidepressant, but its underlying molecular mechanisms remain unclear. Recent studies have emerged microRNAs as important modulators for depression treatment. In this study, we report that miR-98-5p is downregulated in the prefrontal cortex and hippocampus of mice subjected to chronic social stress, while overexpressing it by...

N-methyl-D-aspartate receptor availability in first-episode psychosis: a PET-MR brain imaging study

Translational Psychiatry August 15, 2021 Katherine Beck, Atheeshaan Arumuham, Mattia Veronese et al.

Abstract N-methyl-D-aspartate receptor (NMDAR) hypofunction is hypothesised to underlie psychosis but this has not been tested early in illness. To address this, we studied 40 volunteers (21 patients with first-episode psychosis and 19 matched healthy controls) using PET imaging with an NMDAR selective ligand, [18F]GE-179, that binds to the ketamine binding site to index its distribution volume...

The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study

Translational Psychiatry August 10, 2021 Diego Quattrone, Ulrich Reininghaus, Anne Richards et al.

Diagnostic categories do not completely reflect the heterogeneous expression of psychosis. Using data from the EU-GEI study, we evaluated the impact of schizophrenia polygenic risk score (SZ-PRS) and patterns of cannabis use on the transdiagnostic expression of psychosis. We analysed first-episode psychosis patients (FEP) and controls, generating transdiagnostic dimensions of psychotic symptoms...

Opposite alterations of 5HT2A receptor brain density in subjects with schizophrenia: relevance of radiotracers pharmacological profile

Translational Psychiatry May 20, 2021 Rebeca Dı́ez-alarcia, Carolina Muguruza, Guadalupe Rivero et al. 27 citations

Abstract The status of serotonin 5­HT 2A receptors (5­HT 2A Rs) in schizophrenia has been controversial. In vivo positron emission tomography neuroimaging and in vitro post-mortem binding studies have reported conflicting results about 5­HT 2A R density. Radiotracers bind different receptor conformations depending on their agonist, antagonist or inverse agonist properties. This study...

DOI: 10.1038/s41398-021-01430-7 (opens in new tab) Full text (opens in new tab) Serotonin Inverse agonist Antipsychotic Schizophrenia object-oriented programming +8

A systematic review of neuroimaging and acute cannabis exposure in age-of-risk for psychosis

Translational Psychiatry April 13, 2021 Lani Cupo, Eric Plitman, Elisa Guma et al.

AbstractAcute exposure to cannabis has been associated with an array of cognitive alterations, increased risk for neuropsychiatric illness, and other neuropsychiatric sequelae including the emergence of acute psychotic symptoms. However, the brain alterations associating cannabis use and these behavioral and clinical phenotypes remains disputed. To this end, neuroimaging can be a powerful...

Spontaneous and deliberate creative cognition during and after psilocybin exposure

Translational Psychiatry April 8, 2021 Natasha L. Mason, Kim P. C. Kuypers, Johannes T. Reckweg et al. 132 citations

Abstract Creativity is an essential cognitive ability linked to all areas of our everyday functioning. Thus, finding a way to enhance it is of broad interest. A large number of anecdotal reports suggest that the consumption of psychedelic drugs can enhance creative thinking; however, scientific evidence is lacking. Following a double-blind, placebo-controlled, parallel-group design, we...

Depression treatment response to ketamine: sex-specific role of interleukin-8, but not other inflammatory markers

Translational Psychiatry March 21, 2021 Jennifer L. Kruse, Megha M Vasavada, Richard Olmstead et al. 47 citations

Abstract Inflammation plays a role in depression pathophysiology and treatment response, with effects varying by sex and therapeutic modality. Lower levels of interleukin(IL)-8 predict depression response to antidepressant medication and to electroconvulsive therapy (ECT), although ECT effects are specific to females. Whether IL-8 predicts depression response to ketamine and in a sex-specific...

Neuregulin signaling mediates the acute and sustained antidepressant effects of subanesthetic ketamine

Translational Psychiatry February 24, 2021 Steven F. Grieco, X. Qiao, Kevin Johnston et al.

Subanesthetic ketamine evokes rapid antidepressant effects in human patients that persist long past ketamine’s chemical half-life of ~2 h. Ketamine’s sustained antidepressant action may be due to modulation of cortical plasticity. We find that ketamine ameliorates depression-like behavior in the forced swim test in adult mice, and this depends on parvalbumin-expressing (PV) neuron-directed...

Involvement of NMDA receptors containing the GluN2C subunit in the psychotomimetic and antidepressant-like effects of ketamine

Translational Psychiatry December 1, 2020 Mireia Tarrés-Gatius, Lluis Miquel-Rio, L. Campa et al.

Acute ketamine administration evokes rapid and sustained antidepressant effects in treatment-resistant patients. However, ketamine also produces transient perceptual disturbances similarly to those evoked by other non-competitive NMDA-R antagonists like phencyclidine (PCP). Although the brain networks involved in both ketamine actions are not fully understood, PCP and ketamine activate...

N,N-dimethyltryptamine compound found in the hallucinogenic tea ayahuasca, regulates adult neurogenesis in vitro and in vivo

Translational Psychiatry September 28, 2020 José Á. Morales-García, Javier Calleja‐conde, Jose Antonio López‐moreno et al. 139 citations

Abstract N,N-dimethyltryptamine (DMT) is a component of the ayahuasca brew traditionally used for ritual and therapeutic purposes across several South American countries. Here, we have examined, in vitro and vivo, the potential neurogenic effect of DMT. Our results demonstrate that DMT administration activates the main adult neurogenic niche, the subgranular zone of the dentate gyrus of the...

Modulation of inhibitory control networks relate to clinical response following ketamine therapy in major depression.

Translational Psychiatry July 30, 2020 Ashish K Sahib, Joana Ra Loureiro, Megha M Vasavada et al. 37 citations

Subanesthetic ketamine is found to induce fast-acting and pronounced antidepressant effects, even in treatment resistant depression (TRD). However, it remains unclear how ketamine modulates neural function at the brain systems-level to regulate emotion and behavior. Here, we examined treatment-related changes in the inhibitory control network after single and repeated ketamine therapy in TRD....

A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression

Translational Psychiatry June 26, 2020 Paulo R Shiroma, Paul Thuras, Joseph Wels et al. 112 citations

The strategy of repeated ketamine in open-label and saline-control studies of treatment-resistant depression suggested greater antidepressant response beyond a single ketamine. However, consensus guideline stated the lack of evidence to support frequent ketamine administration. We compared the efficacy and safety of single vs. six repeated ketamine using midazolam as active placebo. Subjects...

Closed-loop digital meditation for neurocognitive and behavioral development in adolescents with childhood neglect.

Translational Psychiatry May 18, 2020 Jyoti Mishra, Rajesh Sagar, Sana Parveen et al.

Adverse childhood experiences are linked to poor attentive behaviors during adolescence, as well as increased risk for mental health disorders in adults. However, no study has yet tested targeted interventions to optimize neurocognitive processes in this population. Here, we investigated closed-loop digital interventions in a double-blind randomized controlled study in adolescents with...

Do AKT1, COMT and FAAH influence reports of acute cannabis intoxication experiences in patients with first episode psychosis, controls and young adult cannabis users?

Translational Psychiatry May 12, 2020 Chandni Hindocha, Diego Quattrone, Tom P. Freeman et al.

Epidemiological and biological evidence support the association between heavy cannabis use and psychosis. However, it is unclear which cannabis users are susceptible to its psychotogenic effect. Therefore, understanding genetic factors contributing to this relationship might prove an important strategy to identify the mechanisms underlying cannabis-associated psychotic experiences. We aimed to...

Association of cannabis with glutamatergic levels in patients with early psychosis: Evidence for altered volume striatal glutamate relationships in patients with a history of cannabis use in early psychosis

Translational Psychiatry April 21, 2020 Musa Sami, Amanda Worker, Marco Colizzi et al.

AbstractThe associative striatum, an established substrate in psychosis, receives widespread glutamatergic projections. We sought to see if glutamatergic indices are altered between early psychosis patients with and without a history of cannabis use and characterise the relationship to grey matter. 92 participants were scanned: Early Psychosis with a history of cannabis use (EPC = 29); Early...

Essential role of microglial transforming growth factor-β1 in antidepressant actions of (R)-ketamine and the novel antidepressant TGF-β1

Translational Psychiatry January 27, 2020 Kai Zhang, Chun Yang, Lijia Chang et al. 120 citations

In rodent models of depression, (R)-ketamine has greater potency and longer-lasting antidepressant effects than (S)-ketamine; however, the precise molecular mechanisms underlying the antidepressant actions of (R)-ketamine remain unknown. Using RNA-sequencing analysis, we identified novel molecular targets that contribute to the different antidepressant effects of the two enantiomers. Either...